W R Bishop
Overview
Explore the profile of W R Bishop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang F, Bishop W
Curr Protoc Pharmacol
. 2011 Oct;
Chapter 3:Unit3.4.
PMID: 21971800
No abstract available.
2.
Liu M, Bishop W, Nielsen L, Bryant M, Kirschmeier P
Methods Enzymol
. 2001 Jun;
333:306-18.
PMID: 11400347
The in vivo evaluation process described here was instrumental in the identification of SCH 66336 as a clinical candidate. Our lead FTI, SCH 66336, and several other FTIs are being...
3.
Kirschmeier P, Whyte D, Wilson O, Bishop W, Pai J
Methods Enzymol
. 2001 Apr;
332:115-27.
PMID: 11305090
No abstract available.
4.
Peters D, Hoover R, GERLACH M, Koh E, Zhang H, Choe K, et al.
Blood
. 2001 Feb;
97(5):1404-12.
PMID: 11222387
BCR/ABL, the oncoprotein responsible for chronic myeloid leukemia (CML), transforms hematopoietic cells through both Ras-dependent and -independent mechanisms. Farnesyl protein transferase inhibitors (FTIs) were designed to block mutant Ras signaling,...
5.
Shi B, Yaremko B, Hajian G, Terracina G, Bishop W, Liu M, et al.
Cancer Chemother Pharmacol
. 2000 Dec;
46(5):387-93.
PMID: 11127943
Purpose: SCH66336 is an orally active, farnesyl protein transferase inhibitor. SCH66336 inhibits ras farnesylation in tumor cells and suppresses tumor growth in human xenograft and transgenic mouse cancer models in...
6.
Ashar H, James L, Gray K, Carr D, McGuirk M, Maxwell E, et al.
Exp Cell Res
. 2000 Dec;
262(1):17-27.
PMID: 11120601
SCH 66336 is a potent farnesyl transferase inhibitor (FTI) in clinical development. It efficiently prevents the membrane association of H-ras, but not K- or N-ras. Yet, in soft agar, it...
7.
Ashar H, Armstrong L, James L, Carr D, Gray K, Taveras A, et al.
Chem Res Toxicol
. 2000 Nov;
13(10):949-52.
PMID: 11080039
No abstract available.
8.
Ashar H, James L, Gray K, Carr D, Black S, Armstrong L, et al.
J Biol Chem
. 2000 Jun;
275(39):30451-7.
PMID: 10852915
Human tumor cell lines that are sensitive to the effects of farnesyl transferase inhibitors accumulate in G(2) --> M (except for cells with an activated Ha-ras that accumulate in G(1))....
9.
Adjei A, Erlichman C, Davis J, Cutler D, Sloan J, Marks R, et al.
Cancer Res
. 2000 Apr;
60(7):1871-7.
PMID: 10766174
Farnesyl protein transferase (FT), an enzyme that catalyzes the first step in the posttranslational modification of ras and a number of other polypeptides, has emerged as an important target for...
10.
Trempus C, Bishop W, Njoroge F, Doll R, Battalora M, Mahler J, et al.
Mol Carcinog
. 2000 Jan;
27(1):24-33.
PMID: 10642434
The Tg.AC mouse carries an activated v-Ha-ras oncogene fused to an embryonic zeta-globin promoter and develops cutaneous papillomas in response to specific chemicals, full thickness wounding, and ultraviolet radiation. Papilloma...